VISTECH grant for Anadis

By Dylan Bushell-Embling
Tuesday, 01 July, 2008

Melbourne's Anadis (ASX: ANX) has been awarded a significant grant from VISTECH for its alimentary mucositis treatment.

The grant is one of only three awarded from VISTECH, a bi-national fund granted by the Victorian and the Israeli Governments, and was awarded through a competitive process including a vigorous scientific assessment.

The US$500,000 grant was awarded to Anadis and its Israeli collaborator Maya BioTech. The money will be used to help fund a clinical trial of polyclonal antibodies, which is expected to take between 18-24 months.

Anadis is predicting to be able to launch a commercial product in as little as two years.

Gastro-intestinal and oral mucositis is a significant side effect of cancer therapy.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd